Plasma Protease C1-Inhibitor Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Plasma Protease C1-Inhibitor Market Analysis
The Plasma Protease C1-inhibitor Treatment Market is expected to experience a significant growth over the forecast period due to the growing incidence of hereditary angioedema (HAE). Hereditary angioedema is a potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi), the global umbrella organization for the world's HAE patient groups.
Additionally, increasing R&D investments, discovery of inhibitor drugs, increasing product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.
Plasma Protease C1-Inhibitor Market Trends
This section covers the major market trends shaping the Plasma Protease C1-Inhibitor Market according to our research experts:
Selective Bradykinin B2 Receptor Antagonist Segment is Expected to Witness Healthy CAGR Over the Forecast Period
A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE). In 2011, Icatibant (Firazyr), a selective bradykinin B2 receptor antagonist, was approved by the US Food and Drug Administration for treatment of acute attacks HAE in adults. Approval was based on 3 double-blind, randomized, controlled clinical trials known as For Angioedema Subcutaneous Treatment (FAST) 1, 2, and 3.
In September 2019, Pharvaris also received a USD 66 Million Series B Financing to Advance the Clinical Development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications.
North America is Found Dominating the Global Plasma Protease C1-inhibitor Market
North America dominates the global Plasma Protease C1-inhibitor market owing to the rising Hereditary Angioedema (HAE) and increasing R&D investments. The other factors also includes presence of well-established healthcare infrastructure, an increasing number of product approvals, and major market players providing effective treatment options to the patients suffering from Hereditary Angioedema in North America.
According to DiscoverHAE, it is estimated that 6,000 people in the United States live with HAE currently. In June 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for its HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. Hence all these factors are expected to drive the overall market in the United States.
Plasma Protease C1-Inhibitor Industry Overview
In Plasma Protease C1-inhibitor market, major players are focusing on various market strategies such as high research and development activities, partnerships, collaborations, acquisitions and mergers etc. Major players in the Plasma Protease C1-inhibitor market are CSL Behring LLC., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., KalVista Pharmaceuticals, Inc amongst others.
Plasma Protease C1-Inhibitor Market Leaders
-
CSL Behring LLC
-
Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
-
Pharming Technologies B.V.
-
KalVista Pharmaceuticals, Inc.
-
BioCryst Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Plasma Protease C1-Inhibitor Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Hereditary Angioedema (HAE)
- 4.2.2 Increasing Investments in the Research & Development Activities
-
4.3 Market Restraints
- 4.3.1 High Price of Esoteric Testing Procedures Restricting Market Entry
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Drug Type
- 5.1.1 C1-inhibitors
- 5.1.2 Kallikrein Inhibitor
- 5.1.3 Selective Bradykinin B2 Receptor Antagonist
-
5.2 By Dosage Form
- 5.2.1 Lyphophlised
- 5.2.2 Injectables
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE
- 6.1 CSL Limited (CSL Behring LLC)
- 6.2 Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
- 6.3 Ionis Pharmaceuticals, Inc.
- 6.4 Pharming Technologies B.V.
- 6.5 Centogene AG
- 6.6 BioCryst Pharmaceuticals
- 6.7 KalVista Pharmaceuticals, Inc.
- 6.8 Fresenius Kabi
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Plasma Protease C1-Inhibitor Industry Segmentation
As per the scope of the report, plasma protease C1 inhibitor (C1 Inh) is a member of the serpin family of protease inhibitors and related proteins, and its mechanism of action is identical to those of the other protease inhibitor members of the family. SERPING1 forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins and fibrinolysis. It is also an efficient FXIIa inhibitor. Mutations of the SERPING1 gene is associated with the adult macular degeneration which causes Hereditary Angioedema (HAE).
| By Drug Type | C1-inhibitors | |
| Kallikrein Inhibitor | ||
| Selective Bradykinin B2 Receptor Antagonist | ||
| By Dosage Form | Lyphophlised | |
| Injectables | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Plasma Protease C1-Inhibitor Market Research FAQs
What is the current Plasma Protease C1-inhibitor Market size?
The Plasma Protease C1-inhibitor Market is projected to register a CAGR of 6.90% during the forecast period (2024-2029)
Who are the key players in Plasma Protease C1-inhibitor Market?
CSL Behring LLC, Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings), Pharming Technologies B.V., KalVista Pharmaceuticals, Inc. and BioCryst Pharmaceuticals are the major companies operating in the Plasma Protease C1-inhibitor Market.
Which is the fastest growing region in Plasma Protease C1-inhibitor Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Plasma Protease C1-inhibitor Market?
In 2024, the North America accounts for the largest market share in Plasma Protease C1-inhibitor Market.
What years does this Plasma Protease C1-inhibitor Market cover?
The report covers the Plasma Protease C1-inhibitor Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Plasma Protease C1-inhibitor Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Plasma Protease C1-inhibitor Industry Report
Statistics for the 2024 Plasma Protease C1-inhibitor market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Plasma Protease C1-inhibitor analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
